Since 2007 Dr. Mandrioli is the chief of the Multidisciplinary Centre for MND in Modena, Italy, a referral centre for diagnosis and treatment of MND and follows 250 patients every year. She created and has been coordinating the population based Registry of ALS in Modena since 2000, and in Emilia Romagna Region (4.4 million inhab.) since 2009. This Registry collects data on patients from 17 Italian neurological centres. She carried out several epidemiological studies on ALS in Italy. She took part, together with ITALSGEN Consortium, in several studies on genetics of ALS that led to the isolation of new genes (including VCP, C9ORF72, MATRIN3, KIF5A), and to pharmacological clinical trials in ALS. She coordinates clinical trials on ALS (currently: RAP-ALS, co-ALS, FETR-ALS). She was coordinator of the Italian Study Group on MND from 2013 to 2017. She has published in over 100 peer-reviewed scientific journals and her work is highly cited by other scientists.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.
Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.